You are here

Clinical Trials

Phase 2/3 trial evaluates dopamine/norepinephrine reuptake inhibitor
The investigational therapy was added to standard of care
Extended-release naltrexone/bupropion superior to usual care
Pivotal study investigates monoclonal antibody
Treatment no better than placebo at some time points
Results may be “game changer” in how brain malignancies are treated, study reports
MYL-1401O improves overall response rate compared with branded product
Prophylactic treatment meets all primary and secondary endpoints
Regulatory submission of single-tablet product expected next year
Treatment fails to improve primary unassisted patency
Antibiotic developed to fight multidrug-resistant infections
Plecanatide replicates function of uroguanylin